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Statistical methods for comparing mortality among ESRD pa- lar emphasis placed on comparisons between patients
tients: Examples of regional/international variations. There receiving in-center hemodialysis (HD) versus those re-
have been a number of recent large-scale registry studies com- ceiving home peritoneal dialysis (PD) [1–3]. On theparing mortality between patients receiving hemodialysis (HD)
surface, the results of some of these studies appear toand peritoneal dialysis (PD). Results from these studies are
contradict one another. For example, the study by Bloem-mixed with some indicating a difference in mortality in favor
of hemodialysis, others finding no difference in mortality and bergen et al [1] shows a survival advantage for hemodial-
still others observing a difference in mortality in favor of perito- ysis patients, the study by Vonesh and Moran [2] shows
neal dialysis. Much of the apparent discrepancy between stud- no difference in survival between hemodialysis and peri-ies might be attributed to differences in study design and analyt-
toneal dialysis, and the study by Fenton et al [3] showsical methods. In this paper, we review and summarize three
a survival advantage for patients receiving peritonealkey methodologies used in the analysis of patient survival data.
These are 1) the type of statistical model used to compare dialysis. It will be shown that these apparent differences
mortality (Cox proportional hazards regression versus Poisson can be attributed largely to methodological differences
regression); 2) the type of analysis used (intent-to-treat versus between the various studies.as-treated); and 3) the type of patient to be studied (prevalent
To help the reader discern why results may differ be-versus incident). The impacts these methodologies have on the
tween studies, we examine three key methodologicalresults of patient survival analysis are illustrated using national
registry data from the U.S. and Canada. We demonstrate that issues that occur in outcomes research, particularly re-
when applied under the same conditions, survival analysis using search related to mortality in end-stage renal disease
Poisson regression versus Cox regression yields essentially (ESRD). The three issues we examine are: 1) whether
equivalent results. However, results of survival analysis may
one should use a Cox proportional hazards model oror may not differ according to whether one uses an intent-to-
a Poisson model when comparing patient survival; 2)treat versus an as-treated analysis, and they almost certainly
will differ when carried out on prevalent versus incident pa- whether one should do an intent-to-treat (ITT) analysis
tients. We also demonstrate that when analyzed using the same or an as-treated analysis; and 3) whether one should use
methodology, results obtained in different countries can be prevalent or incident patients when assessing mortality.
quite similar. One can use either Poisson or Cox regression to
It is our hope that through this exercise, a consensuscarry out patient survival analysis and still achieve similar re-
can be reached regarding which combination of thesesults. In cases where one suspects that the relative risk of death
methods is best suited to outcomes research in ESRD.between PD and HD varies with time, an interval Poisson
or interval Cox regression that includes a modality by time
interaction term is recommended. Other recommendations for
STATISTICAL MODELS FOR MORTAL EVENTS:standardizing patient survival analysis include performing both
an intent-to-treat and as-treated analysis and confining such COX VERSUS POISSON REGRESSION
analyses to incident-only patients.
In analyzing mortality data, one can elect to analyze
either aggregated patient mortality rates or individual
patient survival times. In analyzing aggregated mortalityThere have been a number of recent registry-based
rates, the response or outcome variable is the number of
studies that examine the issue of mortality among pa-
deaths that occur divided by the number of accumulated
tients with end-stage renal disease (ESRD), with particu-
patient-years at risk for death. Analyses based on aggre-
gated mortality rates are common in large-scale epidemi-
ological or registry type studies where information onKey words: end-stage renal disease, Cox proportional hazards, Poisson
regression, relative risk, mortality statistics. mortality is presented in summary form. For example, in
the United States Renal Data System (USRDS) annual 2000 by the International Society of Nephrology
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reports, all-cause mortality rates are summarized ac- ses about the shape of the hazard function although one
can still estimate and describe its shape [11].cording to age, gender, race and diabetic status. Death
rates are computed by dividing the total number of As an alternative to the Cox model, one can carry out
patient survival analysis using an interval Poisson modeldeaths within each possible category by the total number
of patient years at risk within the same category. The (also referred to a piecewise exponential model) [11].
The interval Poisson model is similar to the Cox modeldeath rates are then compared between treatment mo-
dalities using Poisson regression [4–7]. To ensure there in that both account for censored data and assume the
death rates between any two groups of patients will beis a fair comparison, adjustments are often made for
case-mix differences in age, gender, race, diabetic status proportional to one another. Like the Cox model, the
Poisson model also accommodates non-proportionaland other comorbid risk factors. The studies of Bloem-
bergen et al [1] and Vonesh and Moran [2] are examples death rates through the use of time-dependent covari-
ates. However, unlike the Cox model, the Poisson modelof this kind of analysis.
A more common, alternative approach is to examine is semi-parametric in that it assumes death rates are
constant within specified intervals of time. In fact, thistrends in mortality on the basis of individually deter-
mined patient survival times. Here, the response or out- is the key difference between the two models. Specifi-
cally, in the Cox model, the reference population’s deathcome variable is the length of time until the event of
interest takes place (e.g., death) or until some point in rate over a specified interval of time is left unspecified,
while in the Poisson model it is assumed constant. Bothtime where the patient is no longer followed (e.g., a
patient is lost to follow-up or is still alive at the end of models assume the death rate for a comparative group
of patients will be proportional to the death rate for thethe study). When the latter occurs, the patient survival
time is said to be censored. In particular, censoring oc- reference group within each specified interval of time.
For short intervals of follow-up (e.g., every 3 months orcurs whenever the elapsed time to an event is known
only partially. For example, if we let T denote the “sur- every 6 months), it is entirely reasonable to assume that
the death rates will be approximately constant. Conse-vival” time to some event, then T 5 (event time 2 origin
time) where event time is the time the event takes place quently, by choosing appropriate intervals of follow-up,
an interval Poisson model and an interval Cox model(e.g., the date a patient dies) and origin time is a well-
defined starting time from which individuals are followed will give very nearly the same results with respect to
relative risks.(e.g., the date a patient first starts dialysis). If either the
origin time or event time or both are unknown, then the Assuming the underlying death rates for two groups
of patients are roughly proportional to one another over“survival” time is said to be censored; otherwise it is said
to be observed. There are a number of statistical models time (i.e., the relative risk of death is constant over time),
a Cox proportional hazards regression provides a robustthat allow one to analyze patient survival in the presence
of censored data. Below, we describe two such models, method for estimating the relative risk of death. It also
enables one to plot and compare adjusted patient sur-the Cox model and the Poisson model.
Typically, the analysis of individual patient survival vival curves between the two groups without making
any unnecessary assumptions about the underlying deathtimes is carried out using a Cox proportional hazards
regression model [8–11]. The model gets its name, in rates. By excluding any interaction between follow-up
time and treatment modality, one can obtain a similarpart, from the assumption that the hazard function or
death rate for one group of patients will be proportional estimate of relative risk using interval Poisson regression.
However such estimates may vary slightly depending onto the hazard function or death rate from another group.
This is equivalent to assuming the relative risk of death one’s choice of intervals [11].
When the assumption of proportional death rates (i.e.,between the two groups will be constant over time. This
assumption does not require that the death rates them- constant relative risk) is violated, application of the stan-
dard Cox proportional hazards model yields an averageselves be constant in time; it merely requires that their
ratio be constant. When the assumption of proportional- relative risk. In some cases, this average risk may mislead
investigators into thinking one therapy is superior toity is violated, one can still use the Cox model by simply
introducing an appropriate set of time-dependent covari- another when in fact there are periods of time when the
opposite is true. The use of interval Poisson regressionates into the regression [9–12]. One of the chief advan-
tages of the Cox model is that there are no assumptions avoids this by enabling the user to model the relative
risk as a function of time. This is accomplished by includ-regarding what the shape of the underlying hazard or
death rate looks like. It is for this reason that estimates ing an interaction term between the interval follow-up
times and treatment modality. Alternatively, one canof relative risk are more robust under the Cox model
than what might otherwise be obtained using a fully apply an interval Cox proportional hazards model using
the same set-up as for the interval Poisson model. Theparametric model. Unfortunately, this is also a disadvan-
tage in that it does not allow one to formally test hypothe- interval Cox model has the advantage of not assuming
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a constant death rate within each interval of follow-up quently, an ITT analysis attributes death to the patient’s
initial therapy and it does not account for any switchingand so it may be more robust to one’s choice of intervals.
However, it does not allow one to carry out formal hy- of modalities. Unlike with randomized trials, an ITT
analysis among non-randomized ESRD patients servespothesis testing with respect to the shape of the death
rates over time. In any case, one can achieve comparable only to preserve whatever selection bias already exists
between patients on HD versus PD. The rationale usedresults using either a Cox proportional hazards model
or an interval Poisson model provided one has specified most often for doing an ITT analysis is that it provides
useful information to physicians who must make recom-all other aspects of the model the same way (i.e., use of
an ITT analysis, excluding the first 90 days on dialysis, mendations on an initial therapy of choice without
knowledge of any subsequent treatment changes thatetc.).
patients may undergo.
In the randomized trial setting, opponents of the ITT
INTENT-TO-TREAT ANALYSIS VERSUS
approach argue that noncompliant patients, and patients
AS-TREATED ANALYSIS
who switch treatments should be excluded from the anal-
Despite the great flexibility that both the Cox and ysis as these patients no longer receive the benefits of
Poisson models exhibit, there are other issues that need the actual treatment under investigation. Instead, they
to be addressed when analyzing patient survival data. suggest performing an “as-treated” analysis whereby the
One issue is recognizing the potential limitations these measured outcome is ascribed to the actual treatment
models have in the presence of patient dropout. If the the patient is receiving at that time. In most cases, this
cause of dropout is in any way associated with a patient’s will force one to drop patients from an analysis and this
chance for survival, then the patient’s censored survival could lead to biased comparisons. For example, suppose
time is said to be informatively censored. For example, we are comparing an active treatment to a placebo con-
if a patient experiences a serious adverse event while on trol and there is a higher rate of dropout and noncompli-
one therapy, is transferred to another therapy, and dies ance in the group receiving the active treatment. If we
from complications shortly after switching therapies, restrict our analysis to those patients who complete the
then censoring the patient’s survival time at the time of study and who are compliant, we may find the active
switching results in informative censoring. If informative treatment does better than the control. However, we can
censoring exists but is ignored in the analysis, then there no longer be sure that these differences are due to the
is a real danger that the results will be biased. In general, treatment or whether they are due to unforeseen factors
methods for handling informatively censored data can related to compliance and dropout. The fact remains
be extremely complicated especially if one has limited that the two as-treated groups will be different from the
follow-up on those patients who drop out. groups we started with since we have selected out pa-
One approach taken by investigators is to perform tients from the analysis. Hence, we can never be sure
an intent-to-treat (ITT) analysis. In randomized clinical that the benefits observed in the treatment group are
trials, for example, investigators often conduct an ITT truly due to the active treatment or whether they are
analysis whereby all comparisons are made on the basis due to the selection process.
of the groups to which patients were randomized. The Since randomization of patients to HD or PD is a non-
idea is to preserve the benefits of randomization in the issue in ESRD, it is somewhat doubtful that the above
actual comparisons. Specifically, the principles of ran- arguments against an as-treated analysis still hold. In
domization assure us that, on average, patients random- terms of the research question being asked, an as-treated
ized to different treatment groups will be comparable to analysis seeks to determine whether or not a patient’s
one another in terms of both measured and unmeasured current modality will have an effect (again, not necessar-
factors. Consequently, any differences between groups ily causal) on subsequent mortality. As such, the as-
following randomization can safely be ascribed to differ- treated analysis attributes a patient’s death to the ther-
ences in the intended treatments even if some patients apy the patient was on at the time of death or to the
dropout, change treatment, or fail to comply with their patient’s previous therapy provided death occurred
treatment. within a certain transition period (e.g., within 60 days
In ESRD, the ITT approach has been advocated by following a switch in treatment). Thus, unlike the ITT
some researchers as the preferred method of analysis approach, an as-treated analysis accounts for modality
for comparing mortality between HD and PD [13, 14; switches.
abstract, Perit Dial Int 12(Suppl 1):144, 1992]. Here, the There are numerous arguments both for and against
research question being asked is whether a patient’s ini- the ITT and as-treated approaches [14]. In the ESRD
tial treatment modality has any effect (not necessarily setting, the ITT analysis can fail to provide an unbiased
causal) on subsequent mortality regardless of what path estimate of relative risk (RR) between the two treatment
modalities. This is because the death rates attributed tothe patient takes once he or she starts dialysis. Conse-
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PD (and to a lesser extent HD) are actually a mixture
of both PD and HD death rates. If there is a true differ-
ence in mortality rates, then the estimated relative risk
will be attenuated due to the misclassification of patients
by modality. The misclassification arises because some
patients who are receiving HD are classified as being on
PD while some listed as being on HD are actually receiv-
ing PD.
An as-treated analysis allows one to compare purely
HD to purely PD mortality rates. However, it may induce
a certain level of confounding due to competing risks
associated with patient dropout. In particular, if the risk
Fig. 1. Schematic of prevalent versus incident patients. Patients onof switching treatment modality is related to the risk of
dialysis January 1 are said to be point prevalent patients on that date.
death (e.g., a peritoneal dialysis patient with severe fun- New patients who start dialysis between January 1 and December 31
of a given year are said to be incident patients for that cohort period.gal peritonitis is placed on hemodialysis and then dies),
Period prevalent patients are all patients who received any form ofignoring this in an as-treated analysis can produce a dialysis during the cohort period (i.e., period prevalent 5 point preva-
biased comparison. For the most part, this latter objec- lent 1 incident patients).
tion can be handled by simply assigning a transition pe-
riod (e.g., 60 or 90 days) during which the patient’s time
on dialysis and death, if it occurs, is counted against the
hort and an incident cohort. Figure 1 illustrates prevalentinitial treatment modality rather than the new modality.
and incident patients.Given these various caveats, it is probably in the best
Ideally, a statistical analysis would be carried out basedinterest of the investigator to do both types of analysis.
on data from a prospective longitudinal study of new (orWhen reporting the results, the investigator should em-
incident) patients so that the relation between treatmentphasize the research question each type of analysis ad-
modality and outcome may be determined from the on-dresses. When the results from the two analyses are
set of dialysis. This approach avoids any bias that mightsimilar, there are no real concerns. However, when the
occur in a prevalent cohort study as a result of onsettwo approaches yield substantially different conclusions,
confounding [15]. Onset confounding occurs when onea more discerning look at the data is needed in order to
group of prevalent patients has start dates that are veryunderstand the reasons for the discordance. Finally, it
different from a second group of prevalent patients. Inshould be noted that both types of analysis, the ITT
this case, no fair comparison between the two groupsand as-treated, may be carried out using either a Cox
can be made unless the outcome rate (e.g., mortalityproportional hazards model or a Poisson model.
rate) is constant over time. Even in the absence of onset
confounding, other forms of biases exist in prevalent
PREVALENT VERSUS INCIDENT PATIENTS cohort studies that can lead to underestimating or over-
estimating the true relative risk [15]. Assuming the rela-Epidemiological studies comparing dialysis treatment
tive risk is truly constant, such biases appear not to bemodalities are typically carried out using either 1) a prev-
too severe [15]. However, if the relative risk varies withalent cohort of patients, 2) an incident cohort of patients,
time, as would occur with non-proportional death rates,or 3) a combined cohort of prevalent and incident pa-
such biases can be extreme.tients (also known as a period prevalent cohort). By a
Although incident cohorts are ideal, they do requireprevalent cohort, we mean all individuals who, on a given
specifying a patient accrual period during which newdate, manifest a certain condition (e.g., all ESRD pa-
patients are entered into the study. The chief drawbacktients currently on dialysis as of January 1 of a given
to incident-based cohort studies is that they usually re-year). This is commonly referred to as a point prevalent
quire extended periods of time to recruit the necessarycohort because it reflects only those individuals having
number of patients. Consequently, many investigatorsa stated condition at a given point in time. By an incident
include both new (incident) and current (prevalent) pa-cohort, we mean all new individuals who manifest a
tients in their study population. Such studies requirecertain condition within some specified period of time
(e.g., all ESRD patients new to dialysis between January some additional precautions since the biases associated
with a purely prevalent cohort will still be present in a1 and December 31 of a given year). A period-prevalent
cohort is simply a combination of a point-prevalent co- prevalent 1 incident cohort.
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EXAMPLES out by following patients to their time of death, trans-
plantation, or change in treatment modality. PatientsCox versus Poisson
who received a transplant were censored at transplant
To illustrate the preceding points and also demon- while those patients who changed treatment modality
strate some of the similarities and differences in national were censored 60 days following their switch in treat-
registries, we consider data from both the United States ment. Hence, if a death occurred within 60 days following
and Canada. U.S. data includes 195,394 new (incident) a switch, that death and time were ascribed to the initial
Medicare-eligible ESRD patients from 1991–1996 who therapy. Otherwise, the 60 days were ascribed to the
survived the first 90 days of dialysis. Dialysis modality initial therapy. The data were fit using the GENMOD
was determined on the basis of the therapy a patient (interval Poisson model) and PHREG (standard Cox
was receiving at day 90 following the start of renal re- model and interval Cox model) procedures of SAS in
placement therapy. For our purposes, patient demo- accordance with methodology described by Allison [11].
graphics were restricted to gender, age (#55 years, .55 Table 1 summarizes the results for the standard Cox
years), race (blacks, whites), cause of ESRD (diabetes, model and the interval Poisson model assuming propor-
non-diabetes) and treatment modality (hemodialysis, tional hazards (i.e., assuming no modality by time inter-
peritoneal dialysis). Patient follow-up was through June, action). The relative risk for modality shown in Table 1
1997. Canadian data were obtained from the Canadian represents an average relative risk over time. Table 2
Organ Replacement Register for 11,970 incident Cana- compares results between the interval Cox and interval
dian patients starting dialysis from 1990–1994 with fol- Poisson models when one includes a modality by time
low-up through the end of 1994. Treatment comparisons interaction (i.e., when one allows the relative risk to vary
(HD versus PD) were made adjusting for age, primary over time). The 6-month intervals in Table 2 start at 3–9
diagnosis, follow-up time and select pre-dialysis comor- months reflecting the fact that Medicare eligible patients
bid conditions [3]. must survive the first 3 months to be included in the
Our first goal is to demonstrate that differences in analysis. Adjusted death rates and relative risks from
patient survival results as published in the literature are the interval Poisson regression are presented in Figs. 2
not due to differences in the statistical model used (i.e., a and 3 with values centered at the midpoint of each fol-
Cox regression model versus a Poisson regression model) low-up interval. From the results in Table 2, it is clear
but rather to the underlying assumptions used in the that the adjusted relative risk profile for the interval Cox
analysis. To illustrate this, we first compared U.S. mortal- regression looks exactly like that shown in Fig. 2. In fact,
ity rates between HD and PD incident non-diabetic pa- when rounded to two decimal places, the relative risks
tients with adjustment for the main effects of gender, computed from the interval Poisson regression are iden-
age, and race. We confined our analysis to non-diabetic tical to those computed from the interval Cox model.
patients for two reasons. First, there is clear evidence in Further evidence supporting the effective equivalence
the U.S. that non-diabetic patients have a substantially between Poisson and Cox regression is provided using
different risk profile than no diabetics [2, 13, 16, 17; data from the Canadian registry. Shown in Table 3 are
abstract, Perit Dial Int 12(Suppl 1):144, 1992]. This differ- relative risks from both an as-treated and ITT analysis
ence requires that diabetics and non-diabetics be ana- using the Poisson and Cox models. To mimic the U.S.
lyzed separately. Second, previous studies show very lit- data, we included an ITT and as-treated analysis in which
tle interaction between gender, race, age and treatment data were restricted to those patients who survived the
modality among non-diabetics while significant interac- first 90 days on dialysis. Moreover, the as-treated analysis
tions have been shown to exist among diabetics [2, 17]. was carried out with patients censored 60 days after a
Therefore, since a simple main-effects analysis would switch in treatment (i.e., with all deaths and time at risk
be inappropriate for diabetic patients, we confined our during the first 60 days after a switch attributed to the
comparison of the Cox and Poisson models to incident initial therapy). As with the U.S., the Canadian results
non-diabetic patients. shown in Table 3 indicate there is very little difference
We fit the data for 122,711 incident non-diabetic pa- between the Poisson and Cox models.
tients using a 6-month interval Poisson model with and Interestingly, the results in the U.S. are similar to those
without a modality by time interaction. We also fit the in Canada in that the death rates between PD and HD
data to a standard Cox proportional hazards model with appear to violate the proportional hazards assumption.
no modality by time interaction and to a 6-month interval Fenton and colleagues [3, 18] first demonstrated the fact
Cox model with a modality by time interaction. The that mortality rates between HD and PD may not be
former is compared against the interval Poisson model proportional. They found that the unadjusted death rates
with no modality by time interaction while the latter for HD patients initially start off high, then decrease
is compared against the interval Poisson model with a during the first 6–12 months, and then start increasing.
In contrast, the unadjusted PD death rates start consider-modality by time interaction. The analyses were carried
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Table 1. Summary of standard Cox regression and interval Poisson regression assuming proportional hazards
(i.e., assuming a constant relative risk)a
Interval Poisson model without a
Standard Cox model modality by time interaction
Effect RRb 95% Confidence interval RRb 95% Confidence interval
Race (blacks) 0.765 (0.750, 0.779) 0.719 (0.705, 0.733)
Sex (males) 1.018 (1.001, 1.035) 1.039 (1.021, 1.056)
Age ($55 years) 2.604 (2.530, 2.680) 2.746 (2.668, 2.827)
Modality (PD) 0.781 (0.760, 0.801) 0.853 (0.831, 0.875)
a Results are for 122,711 incident U.S. Medicare-eligible non-diabetic patients starting dialysis between 1991–1996
b Reference population: white, female, ,55 years old, HD
Table 2. Summary of interval Cox regression and interval Poisson regression assuming non-proportional hazards
(i.e., assuming the RR varies with time)a
Interval Cox model with a Interval Poisson model with a
modality by time interaction modality by time interaction
Effect RRb 95% Confidence interval RRb 95% Confidence interval
Race (blacks) 0.721 (0.707, 0.734) 0.720 (0.707, 0.734)
Sex (males) 1.039 (1.021, 1.056) 1.039 (1.021, 1.056)
Age ($55 years) 2.746 (2.667, 2.827) 2.746 (2.668, 2.827)
Modality (PD) 3 Time
3–9 months 0.708 (0.676, 0.743) 0.709 (0.676, 0.743)
9–15 months 0.857 (0.811, 0.905) 0.857 (0.811, 0.906)
15–21 months 0.919 (0.860, 0.982) 0.920 (0.861, 0.983)
21–27 months 0.974 (0.901, 1.052) 0.975 (0.902, 1.053)
27–33 months 1.078 (0.985, 1.180) 1.079 (0.987, 1.182)
33–39 months 0.999 (0.893, 1.117) 1.000 (0.893, 1.118)
39–45 months 0.932 (0.809, 1.074) 0.933 (0.810, 1.074)
45–51 months 1.108 (0.938, 1.309) 1.110 (0.939, 1.311)
a Results are for 122,711 incident U.S. Medicare-eligible non-diabetic patients starting dialysis between 1991–1996
b Reference population: white, female, ,55 years old, HD
Fig. 3. Adjusted relative risks (RR PD:HD) and 95% confidence inter-
vals from an interval Poisson regression comparing PD versus HD
patient survival. Results are for incident Medicare-eligible non-diabeticFig. 2. Adjusted death rates (deaths per 1000 patient years) from an
patients from 1991–1996 with follow-up through June 1997. Relativeinterval Poisson regression comparing PD versus HD patient survival.
risks are adjusted for age, gender and race.Results are for all incident Medicare-eligible non-diabetic patients from
1991–1996 with follow-up through June 1997. Death rates are adjusted
for age, gender and race and represent the death rates for patients with
the average characteristics of the population.
gender and race [17]. Clearly neither the PD nor the
HD death rates are constant over time; nor is their risk
ratio (e.g., Fig. 3). While it is not known whether similar
ably lower and gradually increase over time. The trends trends exist in other parts of the world, the results in the
seen in Canada are similar to those shown in Fig. 2 for U.S. and Canada clearly indicate the need to compare
non-diabetic U.S. patients. Similar patterns are seen for modalities using either an interval Poisson or an interval
incident diabetics in the U.S. although the death rate Cox regression with a modality by time interaction term
included in the model.trends and relative risk profiles vary according to age,
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Table 3. Summary of PD:HD relative risks (RR) for Canadian patientsa
Cox model Poisson model
Analysis RRb 95% Confidence interval RRb 95% Confidence interval
As-treatedc (first 90 days included) 0.73 (0.68, 0.79) 0.73 (0.68, 0.79)
As-treatedd (first 90 days included) 0.82 (0.75, 0.90) 0.81 (0.74, 0.89)
As-treatedd (first 90 days excluded) 0.89 (0.82, 0.97) 0.88 (0.81, 0.95)
ITT (first 90 days included) 0.85 (0.78, 0.93) 0.85 (0.78, 0.92)
ITT (first 90 days excluded) 0.93 (0.80, 1.01) 0.93 (0.86, 1.00)
a Relative risks were estimated from a standard Cox regression and from an interval Poisson regression for both an as-treated (with and without censoring) and
intention-to-treat (ITT) analysis. Results are for 11,970 incident patients starting dialysis in Canada between 1990–1994. Relative risks are adjusted for gender,
primary renal diagnosis and pre-dialysis comorbidity [3].
b RR (PD:HD) adjusted for gender, age, primary renal diagnosis and pre-dialysis comorbidity
c As-treated analysis whereby patients who switch therapies have any subsequent patient-years and deaths attributed to the newer therapy
d As-treated analysis whereby patients who switch therapies are censored 60 days following their initial switch
Fig. 5. Adjusted relative risks (RR PD:HD) and 95% confidence inter-Fig. 4. Adjusted relative risks (RR PD:HD) and 95% confidence inter-
vals from an as-treated analysis using interval Poisson regression. Re-vals from an ITT analysis using interval Poisson regression. Results
sults are for 1991–1996 incident Medicare-eligible non-diabetic patientsare for 1991–1996 incident Medicare-eligible non-diabetic patients with
with follow-up through June 1997. Relative risks are adjusted for age,follow-up through June 1997. Relative risks are adjusted for age, gender,
gender, race, interval follow-up time and their two-way interactionsrace, interval follow-up time and their two-way interactions with mod-
with modality.ality.
Intent-to-treat versus as-treated received on day 90). There was a further increase in the
relative risk of death and this is probably due to theAdditional analyses on both Canadian and U.S. data
exclusion of a number of early HD deaths caused bywere carried out to compare results from an as-treated
late referral. For comparison, two ITT analyses wereanalysis versus an ITT analysis. As shown in Table 3,
also done; the first includes data during the first 90 daysresults from the CORR data suggest an as-treated analy-
of dialysis and the second excludes data from the firstsis and an ITT analysis can produce qualitatively differ-
90 days. These two ITT analyses yield slightly higherent results depending on if and how one censors patients
relative risks than their as-treated counterparts (i.e., thewho switch treatment modality. Under the first as-
as-treated analyses where patients are censored 60 daystreated analysis, a patient’s time at risk and death are
following a switch). It is not clear why such differencesattributed to his/her current therapy regardless of how
exist although it very well may reflect a bias in the ITTlong after a switch the patient dies. The second as-treated
analysis whereby, after a reasonable transition period,analysis censors patients 60 days after they initially
patients who switch from PD to HD and subsequentlyswitch treatment modalities. Any death and time at risk
die have their deaths classified under PD.accumulated during that 60-day window are attributed
We performed a similar comparison based on incidentto the initial therapy. Thereafter, the patient is no longer
non-diabetic patients in the U.S. An as-treated analysisfollowed. There was a marked increase in relative risk
was carried out in which patients were censored 60 daysbetween these first two as-treated analyses and this may
following a switch in treatment modality while an ITTwell reflect high initial mortality immediately following
analysis was carried out with only those patients receiv-a switch in treatment modality. The third as-treated anal-
ing a transplant censored. In both cases, we applied anysis duplicates the second except that only those patients
interval Poisson model to compare PD versus HD mor-alive at day 90 are included in the analysis (with patient
modality assigned on the basis of the treatment being tality with adjustment for age, gender, race, interval time
Vonesh et al: Statistical methods for comparing mortalityS-26
Fig. 6. Effect of prevalent versus preva-
lent 1 incident patients on death rate ratios
(RR PD:HD). Adjusted relative risks are
from Poisson regression of USRDS published
mortality rates by cohort periods. Relative
risks are adjusted for age, gender, race, diabe-
tes and their two-way interactions with treat-
ment modality. Symbols are: Women: preva-
lent (h) and prevalent 1 incident ( ). Men:
prevalent (j) and prevalent 1 incident ( ).
Table 4. Impact of prevalent versus incident patients on the adjusted strate what impact the use of prevalent only, prevalent 1
relative risk of deatha
incident and incident only patients have on the adjusted
Patient group RR (PD:HD) 95% Confidence interval relative risk of death among Canadian patients receiving
Prevalent only 0.99 (0.91, 1.07) dialysis (either PD or HD) between 1990–1994.
Prevalent 1 incident 0.80 (0.76, 0.84) Results from other incident cohort studies like that of
Incident only 0.71 (0.67, 0.76)
Held et al [16] tend to agree qualitatively with the inci-
a Relative risks are based on an as-treated analysis Poisson regression with
dent-based analyses presented here. It is when one com-adjustment for age, gender, race, and primary renal diagnosis. Results are for
patients receiving PD or HD in Canada between 1990–1994. pares results from prevalent studies to those from inci-
dent studies that discrepancies begin to appear. To avoid
potential confounding of results due to study design, we
recommend that researchers confine their analyses ofon dialysis, and their two-way interactions with modality.
patient outcomes to incident cohorts of patients. ThisThe results, shown in Figs. 4 and 5, indicate there are
way, one will avoid the potential pitfalls associated withminor differences between the as-treated and ITT analy-
prevalent cohort studies [15].sis, with the majority of the differences occurring toward
the end of the study follow-up period.
DISCUSSIONIncident versus prevalent patients
The analysis of patient survival data is complicated byLastly, we examined what impact the use of prevalent
a number of issues including 1) determining what modelversus incident patients has on patient survival compari-
to use (a Cox proportional hazards model or an intervalsons. In an analysis similar to that presented by Bloem-
Poisson model); 2) deciding on the type of analysis tobergen et al [1], Vonesh et al [2] found that when incident
use (ITT or as-treated analysis); and 3) selecting the type(new) patients are included in the calculation of national
of patient to follow (an incident or prevalent patient).mortality rates, the differences in mortality between PD
With respect to the first issue, we have demonstratedand HD reported by Bloembergen et al essentially disap-
that under the same basic setup (i.e., the same rules forpear. The results of Vonesh et al [2], shown in Fig. 6
censoring patients, the same start dates, etc.), the twoaccording to gender, suggest that the inclusion of new
models give very nearly the same results. Consequently,patients into an analysis of mortality rates dramatically
the user can specify either the Cox or Poisson modelsaffects the estimated relative risk between PD and HD.
and be assured of achieving roughly equal results regard-Vonesh et al speculate that the bias associated with prev-
less of which model was chosen. We recommend usingalent only cohorts stems from the exclusion of first year
an interval Poisson model whenever the focus is on plot-survival benefits associated with PD. Because PD and
ting and comparing adjusted death rates and relativeHD mortality rates are not proportional over time, ex-
risks, particularly if one suspects that these values verycluding incident patients from the 1987–1989 and 1988–
with time. On the other hand, if the investigator were1990 cohorts yields inflated relative risks that favor HD
concerned with plotting and comparing the adjusted sur-over PD. Further support of this is shown in Table 4.
These results, obtained from the CORR data, demon- vival curve, the Cox model would be a better choice.
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